The ambitious prevention study in people with a nearly 100% chance of developing Alzheimer’s disease has failed, and attention will now switch to trial readouts for the next generation of beta-amyloid targeting candidates.

The firm has revealed its anti-tau candidate showed promise in a late-stage Alzheimer’s study several years after a disappointing failure, but data are yet to be announced in full. 

Novartis and Roche may be committed to the target, but AbbVie has decided that its efforts in Parkinson's will not include a Phase II trial of its Swedish partner's alpha synuclein drug.

Advancements in imaging technology may bring medtech and pharma closer together and lead to better drugs for neurological conditions.